PD-1/PD-L1 inhibitors in multiple myeloma: The present and the future

Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F61988987%3A17110%2F17%3AA1801RYK" target="_blank" >RIV/61988987:17110/17:A1801RYK - isvavai.cz</a>
Alternative codes found
RIV/00843989:_____/16:E0106005
Result on the web
<a href="http://dx.doi.org/10.1080/2162402X.2016.1254856" target="_blank" >http://dx.doi.org/10.1080/2162402X.2016.1254856</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1080/2162402X.2016.1254856" target="_blank" >10.1080/2162402X.2016.1254856</a>

Result language
angličtina
Original language name
PD-1/PD-L1 inhibitors in multiple myeloma: The present and the future
Original language description
The introduction of PD-1/PD-L1 pathway inhibitors has marked a significant milestone in the treatment of various types of solid tumors. The current situation in multiple myeloma ( MM) is rather unclear, as distinct research groups have reported discordant results. This discrepancy dominantly concerns the expression of PD-1/PD-L1 molecules as well as the identification of the responsible immune effector cell population. The results of monotherapy with PD-1/PD-L1 inhibitors have been unsatisfactory in MM, suggesting that a combination approach is needed. The most logical partners are immunomodulatory agents as they possess many synergistic effects. We are also proposing other rational and promising combinations (e.g., daratumumab, ibrutinib, anti-CD137) that warrant further investigation.
Czech name
—
Czech description
—

Type
J<sub>imp</sub> - Article in a specialist periodical, which is included in the Web of Science database
CEP classification
—
OECD FORD branch
30205 - Hematology

Publication year
2017
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Similar results(10)